Patents by Inventor Johan HJÄRTSTAM

Johan HJÄRTSTAM has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHARMACEUTICAL COMPOSITION COMPRISING A POTENT INHIBITOR OF URAT1
    Publication number: 20230011269
    Abstract: The present invention relates to pharmaceutical compositions containing 2-((3-(4-cyanonaphthalen-1-yl)pyridine-4-yl)thio)-2-methylpropanoic acid or a pharmaceutically acceptable salt (hereinafter referred to as the “Agent”), more particularly to orally deliverable compositions containing the Agent; to the use of said compositions as a medicament; and to processes for the preparation of said compositions.
    Type: Application
    Filed: June 23, 2022
    Publication date: January 12, 2023
    Inventors: Joanne REILAND WAKEMAN, Colin ROWLINGS, Sha LIU, Gerry BURKE, Christian VON CORSWANT, Christer TANNERGREN, Johan HJÄRTSTAM
  • PHARMACEUTICAL COMPOSITION COMPRISING A POTENT INHIBITOR OF URAT1
    Publication number: 20210113472
    Abstract: The present invention relates to pharmaceutical compositions containing 2-((3-(4-cyanonapthalen-1-yl)pyridin-4-yl)thio)-2-methylpropanoic acid or a pharmaceutically acceptable salt (hereinafter referred to as the “Agent”), more particularly to orally deliverable compositions containing the Agent; to the use of said compositions as a medicament; and to processes for the preparation of said compositions.
    Type: Application
    Filed: August 31, 2020
    Publication date: April 22, 2021
    Inventors: Joanne REILAND WAKEMAN, Colin ROWLINGS, Sha LIU, Gerry BURKE, Christian VON CORSWANT, Christer TANNERGREN, Johan HJÄRTSTAM
  • PHARMACEUTICAL COMPOSITION COMPRISING A POTENT INHIBITOR OF URAT1
    Publication number: 20180360761
    Abstract: The present invention relates to pharmaceutical compositions containing 2-((3-(4-cyanonaphthalen-1-yl)pyridine-4-yl)thio)-2-methylpropanoic acid or a pharmaceutically acceptable salt (hereinafter referred to as the “Agent”), more particularly to orally deliverable compositions containing the Agent; to the use of said compositions as a medicament; and to processes for the preparation of said compositions.
    Type: Application
    Filed: December 7, 2016
    Publication date: December 20, 2018
    Applicants: Ardea Biosciences, Inc., AstraZeneca AB
    Inventors: Joanne REILAND WAKEMAN, Colin ROWLINGS, Sha LIU, Gerry BURKE, Christian VON CORSWANT, Christer TANNERGREN, Johan HJÄRTSTAM